Zoe M. Weinstein, MD, MS

Assistant Professor, Medicine

Zoe Weinstein
617.414.7399
801 Massachusetts Ave Crosstown Center

Biography

Zoe M. Weinstein, MD, MS, is a graduate of Boston University’s Addiction Medicine Fellowship and board certified in Internal Medicine and Addiction Medicine. She has been the Director of Boston Medical Center’s interdisciplinary addiction consult service since July 2016. She has been NIDA grant funded as a co-investigator on multiple studies to deliver training and technical assistance to interdisciplinary provider teams (physicians, nurse practitioners, social workers, addiction counselors and recovery coaches) to expand treatment for opioid use disorder among hospitalized patients in New York City public hospitals as well as hospitals in Massachusetts as part of the HEALing Communities Study. She is currently site-PI of two NIDA Clinical Trial Network studies focused on inpatient addiction care. Her clinical and research work are also focused on long-term Office-Based Addiction Treatment (OBAT) with buprenorphine. She currently serves as Associate Director of Boston University’s Addiction Medicine Fellowship Program, a board member of AMERSA and is a site medical director of a local methadone clinic.

Other Positions

  • Faculty, Clinical Addiction Research and Education Unit, Medicine, Boston University Chobanian & Avedisian School of Medicine

Education

  • University of California San Francisco, MD
  • Columbia University, BA

Publications

  • Published on 2/7/2023

    Rozansky H, Awtry E, Weinstein ZM, Peterkin AF. Grayken lessons: the role of an interdisciplinary endocarditis working group in evaluating and optimizing care for a woman with opioid use disorder requiring a second tricuspid valve replacement. Addict Sci Clin Pract. 2023 Feb 07; 18(1):9. PMID: 36750906.

    Read at: PubMed
  • Published on 1/25/2023

    Peterkin AF, Jawa R, Menezes K, You J, Cabral H, Ruiz-Mercado G, Park TW, Kehoe J, Taylor JL, Weinstein ZM. Pre-Paid Phone Distribution: A Tool for Improving Healthcare Engagement for People with Substance Use Disorder. Subst Use Misuse. 2023; 58(4):585-589. PMID: 36695079.

    Read at: PubMed
  • Published on 1/9/2023

    Laks J, Walley AY, Bagley SM, Barber CM, Gaeta JM, Neville LA, Peterkin AF, Rosenthal E, Saia KA, Weinstein ZM, Harris MTH. Developing a Women's Health track within addiction medicine fellowship: reflections and inspirations. Addict Sci Clin Pract. 2023 Jan 09; 18(1):3. PMID: 36617557.

    Read at: PubMed
  • Published on 11/11/2022

    Sulakvelidze N, Ronan C, Peterkin AF, Weinstein ZM. Efficacy of Low-Dose Versus Traditional Buprenorphine Induction in the Hospital: A Quantitative and Qualitative Study. Am J Ther. 2023 Jan-Feb 01; 30(1):e1-e9. PMID: 36608069.

    Read at: PubMed
  • Published on 7/26/2022

    Calcaterra SL, Bottner R, Martin M, Englander H, Weinstein ZM, Weimer MB, Lambert E, Ronan MV, Huerta S, Zaman T, Ullal M, Peterkin AF, Torres-Lockhart K, Buresh M, O'Brien MT, Snyder H, Herzig SJ. Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines. J Hosp Med. 2022 Sep; 17(9):679-692. PMID: 35880821.

    Read at: PubMed
  • Published on 7/26/2022

    Calcaterra SL, Martin M, Bottner R, Englander H, Weinstein Z, Weimer MB, Lambert E, Herzig SJ. Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine. J Hosp Med. 2022 Sep; 17(9):744-756. PMID: 35880813.

    Read at: PubMed
  • Published on 6/27/2022

    Buresh M, Nahvi S, Steiger S, Weinstein ZM. Adapting methadone inductions to the fentanyl era. J Subst Abuse Treat. 2022 Oct; 141:108832. PMID: 35870437.

    Read at: PubMed
  • Published on 5/18/2022

    Datar Y, Yin K, Wang Y, Lawrence KW, Awtry EH, Cervantes-Arslanian AM, Kimmel SD, Fagan MA, Weinstein ZM, Karlson KJ, McAneny DB, Edwards NM, Dobrilovic N. Surgical outcomes of pulmonary valve infective endocarditis: A US population-based analysis. Int J Cardiol. 2022 Aug 15; 361:50-54. PMID: 35597492.

    Read at: PubMed
  • Published on 5/14/2022

    Taylor JL, Laks J, Christine PJ, Kehoe J, Evans J, Kim TW, Farrell NM, White CS, Weinstein ZM, Walley AY. Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care. Drug Alcohol Depend. 2022 Jul 01; 236:109497. PMID: 35607834.

    Read at: PubMed
  • Published on 4/6/2022

    Shankar D, Borrelli B, Cobb V, Quintiliani LM, Palfai T, Weinstein Z, Bulekova K, Kathuria H. Text-messaging to promote smoking cessation among individuals with opioid use disorder: quantitative and qualitative evaluation. BMC Public Health. 2022 Apr 06; 22(1):668. PMID: 35387648.

    Read at: PubMed

View 33 more publications: View full profile at BUMC

View all profiles